Corporate$AGIO11:05 AM ET

Agios Pharmaceuticals shares fall on FDA review extension for sickle cell drug

By BORSA NewsroomPublished Oct 30, 2026, 11:05 AM EDTUpdated Oct 30, 2026, 11:06 AM EDT

Agios Pharmaceuticals dropped 19% to $30.26 after the FDA extended the review goal date for mitapivat to Feb. 1. The extension follows an FDA request for additional REMS-related information. Agios said the benefit-risk profile remains unchanged.

Sentimentbearish 20

Strongly bearish · 20 of 100

Impact60

medium · sector-wide

Confidence80%

high confidence · single wire

Eventdeveloping

v1 · alerted to followers

WHAT WE KNOW

FDA extended goal date to Feb. 1
Original goal date was three months earlier